Literature DB >> 6723331

Plasma fibronectin in medical ICU patients.

M T O'Connell, D M Becker, B W Steele, G S Peterson, R L Hellman.   

Abstract

Plasma fibronectin levels in 66 medical ICU (MICU) patients were measured daily. Mean values of initial levels were significantly higher in survivors (266 +/- 14 mg/L) than nonsurvivors (179 +/- 13 mg/L; p less than .0003). There was extensive overlap between survivors and nonsurvivors. The clinical categories of sepsis, disseminated intravascular coagulation (DIC), adult respiratory distress syndrome (ARDS), and hepatic failure with GI bleeding were associated with low fibronectin levels. Within all diagnostic categories the mean initial fibronectin level of the survivors was higher than that of nonsurvivors. This difference was significant only in the septic group (p less than .02). Patients with minimum fibronectin levels less than 195 mg/L had a 65% mortality rate; patients with minimum levels greater than or equal to 195 mg/L had a 17% mortality rate. Fibronectin, via its role in reticuloendothelial system (RES) function, may have a pathophysiologic role in a variety of medical illnesses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6723331     DOI: 10.1097/00003246-198406000-00001

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

1.  Plasma fibronectin and complement following infusion of colloidal solutions after spinal anaesthesia.

Authors:  J M Vedrinne; J P Hoen; D Bussery; C Veyssere; M Richard; J Motin
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

2.  Plasma fibronectin and the critically ill.

Authors:  J K Czop
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

Review 3.  Plasma fibronectin: relevance for anesthesiology and intensive care.

Authors:  J E Doran; P Lundsgaard-Hansen; E Rubli
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

4.  Changes in plasma fibronectin isoform levels predict distinct clinical outcomes in critically ill patients.

Authors:  John H Peters; Mark N Grote; Nancy E Lane; Richard J Maunder
Journal:  Biomark Insights       Date:  2011-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.